Literature DB >> 33432658

Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis.

Joyce S Lee1, Janet La2, Sara Aziz2, Evgenia Dobrinskikh1, Robert Brownell2, Kirk D Jones3, Natalia Achtar-Zadeh2, Gary Green2, Brett M Elicker4, Jeffrey A Golden2, Michael A Matthay2, Jasleen Kukreja5, David A Schwartz1, Paul J Wolters1.   

Abstract

AIMS: Idiopathic pulmonary fibrosis (IPF) is a genetically mediated, age-associated, progressive form of pulmonary fibrosis characterised pathologically by a usual interstitial pneumonia (UIP) pattern of fibrosis. The UIP pattern is also found in pulmonary fibrosis attributable to clinical diagnoses other than IPF (non-IPF UIP), whose clinical course is similarly poor, suggesting common molecular drivers. This study investigates whether IPF and non-IPF UIP lungs similarly express markers of telomere dysfunction and senescence. METHODS AND
RESULTS: To test whether patients with IPF and non-IPF UIP share molecular drivers, lung tissues from 169 IPF patients and 57 non-IPF UIP patients were histopathologically and molecularly compared. Histopathological changes in both IPF and non-IPF UIP patients included temporal heterogeneity, microscopic honeycombing, fibroblast foci, and dense collagen fibrosis. Non-IPF UIP lungs were more likely to have lymphocytic infiltration, non-caseating granulomas, airway-centred inflammation, or small airways disease. Telomeres were shorter in alveolar type II (AECII) cells of both IPF and non-IPF UIP lungs than in those of age-similar, unused donor, controls. Levels of molecular markers of senescence (p16 and p21) were elevated in lysates of IPF and non-IPF UIP lungs. Immunostaining localised expression of these proteins to AECII cells. The mucin 5B (MUC5B) gene promoter variant minor allele frequency was similar between IPF and non-IPF UIP patients, and MUC5B expression was similar in IPF and non-IPF UIP lungs.
CONCLUSIONS: Molecular markers of telomere dysfunction and senescence are pathologically expressed in both IPF and non-IPF UIP lungs. These findings suggest that common molecular drivers may contribute to the pathogenesis of UIP-associated pulmonary fibrosis, regardless of the clinical diagnosis.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  alveolar type II cell; hypersensitivity pneumonitis; interstitial lung disease; pulmonary fibrosis; rheumatoid arthritis; scleroderma; senescence; telomere

Mesh:

Substances:

Year:  2021        PMID: 33432658      PMCID: PMC8195814          DOI: 10.1111/his.14334

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   7.778


  43 in total

1.  miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence.

Authors:  Huachun Cui; Jing Ge; Na Xie; Sami Banerjee; Yong Zhou; Veena B Antony; Victor J Thannickal; Gang Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

4.  Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.

Authors:  Pierre-Antoine Juge; Raphaël Borie; Caroline Kannengiesser; Steven Gazal; Patrick Revy; Lidwine Wemeau-Stervinou; Marie-Pierre Debray; Sébastien Ottaviani; Sylvain Marchand-Adam; Nadia Nathan; Gabriel Thabut; Christophe Richez; Hilario Nunes; Isabelle Callebaut; Aurélien Justet; Nicolas Leulliot; Amélie Bonnefond; David Salgado; Pascal Richette; Jean-Pierre Desvignes; Huguette Lioté; Philippe Froguel; Yannick Allanore; Olivier Sand; Claire Dromer; René-Marc Flipo; Annick Clément; Christophe Béroud; Jean Sibilia; Baptiste Coustet; Vincent Cottin; Marie-Christophe Boissier; Benoit Wallaert; Thierry Schaeverbeke; Florence Dastot le Moal; Aline Frazier; Christelle Ménard; Martin Soubrier; Nathalie Saidenberg; Dominique Valeyre; Serge Amselem; Catherine Boileau; Bruno Crestani; Philippe Dieudé
Journal:  Eur Respir J       Date:  2017-05-11       Impact factor: 16.671

5.  Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance.

Authors:  Louise Hecker; Naomi J Logsdon; Deepali Kurundkar; Ashish Kurundkar; Karen Bernard; Thomas Hock; Eric Meldrum; Yan Y Sanders; Victor J Thannickal
Journal:  Sci Transl Med       Date:  2014-04-09       Impact factor: 17.956

6.  Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis.

Authors:  Ping Wang; Kirk D Jones; Anatoly Urisman; Brett M Elicker; Thomas Urbania; Kerri A Johannson; Deborah Assayag; Joyce Lee; Paul J Wolters; Harold R Collard; Laura L Koth
Journal:  Chest       Date:  2017-02-20       Impact factor: 9.410

7.  The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Cell Biol       Date:  2010-06-06       Impact factor: 28.824

8.  Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening.

Authors:  Bridget D Stuart; Jungmin Choi; Samir Zaidi; Chao Xing; Brody Holohan; Rui Chen; Mihwa Choi; Pooja Dharwadkar; Fernando Torres; Carlos E Girod; Jonathan Weissler; John Fitzgerald; Corey Kershaw; Julia Klesney-Tait; Yolanda Mageto; Jerry W Shay; Weizhen Ji; Kaya Bilguvar; Shrikant Mane; Richard P Lifton; Christine Kim Garcia
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 41.307

9.  Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo.

Authors:  Mareike Lehmann; Martina Korfei; Kathrin Mutze; Stephan Klee; Wioletta Skronska-Wasek; Hani N Alsafadi; Chiharu Ota; Rita Costa; Herbert B Schiller; Michael Lindner; Darcy E Wagner; Andreas Günther; Melanie Königshoff
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

10.  miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Supparerk Disayabutr; Eun Kyung Kim; Seung-Ick Cha; Gary Green; Ram P Naikawadi; Kirk D Jones; Jeffrey A Golden; Aaron Schroeder; Michael A Matthay; Jasleen Kukreja; David J Erle; Harold R Collard; Paul J Wolters
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

View more
  7 in total

1.  Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival.

Authors:  Jonathan Keow; Matthew J Cecchini; Nathashi Jayawardena; Maurizio Zompatori; Mariamma G Joseph; Marco Mura
Journal:  Respir Res       Date:  2022-06-07

2.  Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis.

Authors:  Haruhiko Furusawa; Anna L Peljto; Avram D Walts; Jonathan Cardwell; Philip L Molyneaux; Joyce S Lee; Evans R Fernández Pérez; Paul J Wolters; Ivana V Yang; David A Schwartz
Journal:  Thorax       Date:  2022-01-07       Impact factor: 9.102

Review 3.  From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?

Authors:  Jacob E Michalski; Jonathan S Kurche; David A Schwartz
Journal:  Transl Res       Date:  2021-09-20       Impact factor: 10.171

4.  Cut from the Same Cloth: Similarities between Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis.

Authors:  Monica M Yang; Paul J Wolters
Journal:  Am J Respir Crit Care Med       Date:  2022-01-01       Impact factor: 21.405

5.  GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar epithelial cells.

Authors:  Rafael Jesus Fernandez; Zachary J G Gardner; Katherine J Slovik; Derek C Liberti; Katrina N Estep; Wenli Yang; Qijun Chen; Garrett T Santini; Javier V Perez; Sarah Root; Ranvir Bhatia; John W Tobias; Apoorva Babu; Michael P Morley; David B Frank; Edward E Morrisey; Christopher J Lengner; F Brad Johnson
Journal:  Elife       Date:  2022-05-13       Impact factor: 8.713

6.  Lack of ZNF365 Drives Senescence and Exacerbates Experimental Lung Fibrosis.

Authors:  Juan Urista; Mariel Maldonado; Fernanda Toscano-Marquez; Remedios Ramírez; Yalbi Itzel Balderas-Martínez; Carina Becerril; Yair Romero; Moisés Selman; Annie Pardo
Journal:  Cells       Date:  2022-09-13       Impact factor: 7.666

Review 7.  Telomeres in Interstitial Lung Disease.

Authors:  Carmel J W Stock; Elisabetta A Renzoni
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.